« » View all News

CPTR and SIMCYP launch models to evaluate exposure and efficacy of TB drugs in combination

The Critical Path to TB Drug Regimens (CPTR) Initiative and SIMCYP have partnered to develop a TB-specific set of models and compound files to inform the design of first-in-human trials that will simultaneously evaluate the exposure and efficacy of novel anti-TB combination regimens of up to 4 drugs.

This collection of models is comprised of:

These components will be integrated into SIMCYP version 16, which is a well-established platform, widely-adopted by industry and regulators for optimizing clinical trial design. With TB-specific tools, development teams and regulators evaluating novel TB regimens will have a robust tool to optimize clinical trial design for first-in-human studies.

« » View all News